CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations

62-21-365-WC IDWeek Reg Banner_Art
Proprietary Educational Format:

Activity Overview

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

0.75 CE Credit(s)
Expires: November 8, 2022

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Chemaly 500x500

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ

Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX

SILVEIRA_FERNANDA_MD_ID_20180124

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA